What is the European Medicines Agency?

Epidemiology and Psychiatric Sciences

Volumn 21, Issue 3, 2012, Pages 245-247

  Bighelli, I ^a   Barbui, C ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

bias; drug approval; methods; randomized controlled trial

Indexed keywords

AGOMELATINE; ARIPIPRAZOLE; DULOXETINE; MELATONIN; OLANZAPINE; PALIPERIDONE; PREGABALIN; ZALEPLON;

ARTICLE; DRUG APPROVAL; EUROPEAN MEDICINES AGENCY; HEALTH CARE ORGANIZATION; HUMAN;

DRUG APPROVAL; EUROPE; GOVERNMENT AGENCIES; HUMANS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864608963     PISSN: 20457960     EISSN: 20457979     Source Type: Journal    
DOI: 10.1017/S2045796012000170     Document Type: Article

References (12)

1. Barbui C, Baschirotto C, Cipriani A (2011). EMA must improve the quality of its clinical trial reports. British Medical Journal 342, 1187-1189.
2. Barbui C, Garattini S (2007). Regulatory policies on medicines for psychiatric disorders: is Europe on target? British Journal of Psychiatry 190, 91-93.
3. Cipriani A, Furukawa TA, Barbui C (2011). What is a Cochrane review? Epidemiology and Psychiatric Sciences 20, 231-233.
4. Cipriani A, Geddes JR (2009). What is a randomised controlled trial? Epidemiologia e Psichiatria Sociale 18, 191-194.
5. EMA Committee for Medicinal Products for Human Use (2010). Guideline on clinical investigation of medicinal products in the treatment of depression (http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2011/10/WC500116160.pdf).
6. EMA Committee for Medicinal Products for Human Use (2011). Guideline on clinical investigation of medicinal products in the treatment of schizophrenia (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/ 02/WC500102292.pdf).
7. Garattini S (2005). EMEA: for patients or for industry? Pharmacoeconomics 23, 207-208. (Pubitemid 40663627)
8. Garattini S, Bertele' V (2007). Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370, 1875-1877. (Pubitemid 350180009)
9. Garattini S, Chalmers I (2009). Patients and the public deserve big changes in evaluation of drugs. British Medical Journal 338, b1025.
10. Gotzsche PC, Jorgensen AW (2011). Opening up data at the European Medicines Agency. British Medical Journal 342, d2686.
11. Lancet (2010). European Medicines Agency-more transparency needed. Lancet 375, 1753.
12. Sorenson C, Naci H, Cylus J, Mossialos E (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal 343, d4849.